Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Zymeworks Inc (Zymeworks) is a biotechnology company developing a multifunctional biotherapeutics to treat cancer, inflammation, and autoimmune disease. The company’s pipeline products include ZW191 for advanced solid tumors; ZW251 targets hepatocellular carcinoma; ZW220 which treats ovarian cancer and non-small cell lung cancer; ZW209 and ZW1528. Zymeworks also offers zanidatamab, a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2) that treats gastroesophageal adenocarcinomas, biliary tract, gastrointestinal and breast cancer. The company operates through its subsidiaries in the US, Ireland, Canada, the UK and Singapore. Zymeworks is headquartered in Middletown, Delaware, the US.
Headquarters
United States of America
Address
Suite A, 108 Patriot Drive, Middletown, Delaware, 19709
Website
www.zymeworks.com
Telephone
1 302 2748744
No of Employees
264
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ZYME (NASD)
Revenue (2024)
$106.0M
38.9%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
33.9%
(2024 vs 2023)
Market Cap*
$1.7B
Net Profit Margin (2024)
XYZ
52.4%
(2024 vs 2023)
* As of and is in US$
Zymeworks Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | Azymetric |
| ZW191: Advanced Solid Tumors | EFECT |
| ZW251: Hepatocellular Carcinoma | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Regulatory Approval | In May, the company secured approval from the National Medical Products Administration for zanidatamab to treat patients with previously treated, unresectable or metastatic HER2-positive (HER2+) biliary tract cancer. |
| 2024 | Regulatory Approval | In July, the company received approval from the United States Food and Drug Administration for the new drug application for ZW191, the Company’s novel folate receptor-⍺ (FR⍺) targeted topoisomerase I inhibitor (TOPO1i) antibody-drug conjugate. |
| 2024 | Regulatory Approval | In June, the company received approval from the Center for Drug Evaluation of China's National Medical Products Administration for a biologics license application for zanidatamab as a second-line treatment for HER2-positive BTC. |
Competitor Comparison
| Key Parameters | Zymeworks Inc | Seagen Inc | Puma Biotechnology Inc | MacroGenics Inc | Sutro Biopharma Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Middletown | Bothell | Los Angeles | Rockville | South San Francisco |
| State/Province | Delaware | Washington | California | Maryland | California |
| No. of Employees | 264 | 3,256 | 179 | 293 | 137 |
| Entity Type | Public | Private | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Kenneth Galbraith | Chairman; Chief Executive Officer | Executive Board | 2022 | 63 |
| Kristin Stafford | Chief Financial Officer | Senior Management | 2026 | - |
| Mark Hollywood | Chief Operating Officer; Executive Vice President | Senior Management | 2026 | - |
| Sabeen Mekan, M.D. | Chief Medical Officer; Senior Vice President | Senior Management | 2026 | - |
| Paul A. Moore, Ph.D | Chief Scientific Officer | Senior Management | 2022 | 59 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer